Cancer peptide therapy Parabilis is sprinting to NASDAQ! Parabilis (PBLS.US) plans to raise $450 million and debut on the U.S. stock market with a market value of $2.6 billion.

Focused on cancer treatment, the American biotechnology company Parabilis Medicines confirmed its $450 million IPO terms on June 3 Eastern Time. Parabilis Medicines is a biotechnology company in the clinical trial stage, developing engineered peptide therapies for cancer treatment. The company, headquartered in Cambridge, Massachusetts, plans to raise approximately $450 million by issuing 25 million shares of stock at a price range of $17 to $19 per share. Based on the proposed mid-point of the range, Parabilis Medicines' market value will reach $2.6 billion. Parabilis Medicines is a clinical-stage biotechnology company developing drugs targeting proteins that were previously considered "undruggable". Formerly known as FOG Pharmaceuticals, the company's proprietary Helicon platform can produce stabilized helical peptides aimed at regulating protein-protein interactions inside cells that traditional small molecules or biologics cannot reach. Its lead candidate drug zolucatetide targets the Wnt/-catenin pathway, which drives a wide range of solid tumors; over 150 patients have received zolucatetide treatment to date. The core technology of Pharmaceuticals is not traditional small molecules, antibodies, or cell therapy, but its proprietary Helicon stabilized helical peptide platform: by engineering peptide molecules to enter cells, it regulates protein-protein interactions previously considered "undruggable," particularly targeting cell-intrinsic cancer driver targets that traditional drugs have difficulty covering. The Helicon therapy is described as "alpha-helically locked peptides" on the company's official website and is designed and optimized using AI and physical computing methods. In a clinical trial for its main indication fibromatosis, 38 patients have been enrolled and treated with zolucatetide; among 25 patients with sufficient follow-up and assessable efficacy response, all 25 (100%) showed tumor reduction, and among 19 patients who completed scans after two baselines, 14 (74%) achieved objective relief according to RECIST 1.1 criteria. The company plans to initiate a Phase 3 registration clinical trial for fibromatosis in the first half of 2027. The company is also evaluating the potential of zolucatetide as a treatment for familial adenomatous polyposis (FAP), an orphan disease. Parabilis has previously received support from Wall Street financial giants Fidelity and RA Capital, raising nearly $1 billion through private financing, with the most recent round raising over $300 million in January. Parabilis Medicines was founded in 2015 and plans to list on the NASDAQ under the code "PBLS". Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital are the joint bookrunners for this transaction. The transaction is expected to be priced in the week of June 8, 2026. This emerging clinical-stage biotechnology company focused on cancer treatment is still in the clinical stage, with its core growth path not in existing drug sales revenue, but in future commercialization revenue, indication expansion, platform pipeline development, and external cooperation agreements after drug approval. The IPO financing logic mainly revolves around three points: advancing late-stage clinical trials for zolucatetide, expanding the application of the Helicon platform in "undruggable" targets, and realizing platform value through collaboration with large pharmaceutical companies; for example, the company has entered into a strategic partnership with Regeneron to combine the Helicon peptide platform with Regeneron's antibody capabilities, developing new Antibody-Helicon Conjugates.